To test our hypothesis postulating that compounds selected by in silico analysis can correct ΔF508-CFTR function, we evaluated the effects of these compounds on several ΔF508-CFTR parameters: protein processing and channel function in three cell lines (HeLa, CF-KM4) and on human bronchial primary epithelial cells from CF patients (CF-HBE) as well as in vivo analysis of nasal potential difference in ΔF508/ΔF508 mice. This evidence concerns the gene CFTR and cystic fibrosis.